Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04427501 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,307
- Enrollment target
NCT04427501: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT04427501 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 3,307 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2386% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04427501, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,307 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 22), open-label addendum to evaluate the pharmacokinetics and safety of LY3819253 and LY3832479. Enrollment began on March 31, 2021, and completed on September 24, 2021. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 23), open-label addendum to evaluate the pharmacokinetics and safety of LY3853113. Enrollment began on August 19, 2022, and completed on February 21, 2023.
Primary Outcome
COVID-19 Related Deterioration (yes/no) was defined as a participant experiencing COVID-19-related hospitalization (defined as 24 hours of acute care) or death from any cause by Day 29.
Interventions
- DRUG Placebo
- DRUG LY3819253
- DRUG LY3832479
- DRUG LY3853113
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,307 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 2 |
What the finished NCT04427501 record still lists
NCT04427501 is an interventional study that assigns participants to a tested intervention. Its 3,307 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2386% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04427501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04427501 about?
NCT04427501 is a clinical study titled "A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness". The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at v...
What is the current status of trial NCT04427501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,307 participants. The study started on 2020-06-17. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT04427501?
The interventions under investigation include: Placebo (DRUG), LY3819253 (DRUG), LY3832479 (DRUG), LY3853113 (DRUG).
Who is sponsoring clinical trial NCT04427501?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04427501's enrollment target sits among peer trials
3,307 6th of 2000 higher than 1,995 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI